Related Experiment Video
Updated: Mar 2, 2026

Deep Neuromuscular Blockade Leads to a Larger Intraabdominal Volume During Laparoscopy
Published on: June 25, 2013
Sugammadex ED90 dose to reverse the rocuronium neuromuscular blockade in obese patients
Mauro Prado DA Silva1, Christiano Matsui1, Daniel Dongiou Kim1
1- Central Hospital, Brotherhood of the Santa Casa de Misericórdia de São Paulo, Sevice of Anesthesiology, Sao Paulo, São Paulo State, Brazil.
Objective:
to determine the ED90 (minimum effective dose in 90% of patients) of sugammadex for the reversal of rocuronium-induced moderate neuromuscular blockade (NMB) in patients with grade III obesity undergoing bariatric surgery.
Methods:
we conducted a prospective study with the biased coin up-and-down sequential design. We chosen the following doses: 2.0mg/Kg, 2.2mg/Kg, 2.4mg/Kg, 2.6mg/Kg, 2.8mg/Kg. The complete reversal of rocuronium-induced NMB considered a T4/T1 ratio ≥0.9 as measured by TOF. After induction of general anesthesia and calibration of the peripheral nerve stimulator and accelerometer, we injected rocuronium 0.6mg/kg. We administered propofol and remifentanil by continuous infusion, and intermittent boluses of rocuronium throughout the procedure.
Results:
we evaluated 31 patients, of whom 26 had displayed successful reversal of the NMB with sugammadex, and failure in five. The mean time to complete moderate NMB reversal was 213 seconds (172-300, median 25-75%). The ED90 of sugammadex calculated by regression was 2.39mg/kg, with a 95% confidence interval of 2.27-2.46 mg/kg.
Conclusion:
the ED90 of sugammadex in patients with grade III obesity or higher was 2.39mg/kg.
Insights
The minimum effective dose (ED90) of sugammadex for reversing moderate neuromuscular blockade induced by rocuronium in obese patients undergoing bariatric surgery was determined to be 2.39 mg/kg.
Area of Science:
- Anesthesiology
- Pharmacology
Background:
- Neuromuscular blockade (NMB) reversal is critical in surgery.
- Obesity can affect drug pharmacokinetics, potentially altering NMB reversal efficacy.
Purpose of the Study:
- To determine the ED90 (minimum effective dose in 90% of patients) of sugammadex for reversing rocuronium-induced moderate NMB.
- To evaluate sugammadex efficacy in patients with grade III obesity undergoing bariatric surgery.
Main Methods:
- Prospective study utilizing a biased coin up-and-down sequential design.
- Rocuronium 0.6 mg/kg was administered, with sugammadex doses ranging from 2.0 to 2.8 mg/kg.
- Complete NMB reversal was defined as a T4/T1 ratio ≥0.9, measured by TOF.
Main Results:
- 31 patients were evaluated; 26 showed successful reversal, and 5 experienced failure.
- The mean time to complete NMB reversal was 213 seconds.
- The calculated ED90 of sugammadex was 2.39 mg/kg (95% CI: 2.27-2.46 mg/kg).
Conclusions:
- The ED90 of sugammadex for reversing moderate rocuronium-induced NMB in patients with grade III obesity is 2.39 mg/kg.
- Sugammadex demonstrates effective reversal of NMB in this specific patient population.
Related Concept Videos
Drug Dosing: Obese Patients
Skeletal Muscle Relaxants: Therapeutic Uses
Depolarizing Blockers: Pharmocokinetics
Skeletal Muscle Relaxants: Adverse Effects
Unlike...
Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacological Actions
Although all competitive neuromuscular blockers are designed...
Nondepolarizing (Competitive) Neuromuscular Blockers: Pharmacokinetics
Instead, they are transported by the blood to different tissues. Muscles with a greater blood supply (arteries) and blood flow receive more...

